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Introduction 
The Innovative Medicines Initiative (IMI) is a Joint Technology Initiative (JTI) between the European 
Union, represented by the European Commission (EC), and the European Federation of 
Pharmaceutical Industries and Associations (EFPIA). IMI is currently the world’s largest PPP in the 
biomedical sciences (Box 1). The IMI was set up to boost the competitiveness of Europe in the 
biopharmaceutical field and was launched in 2008 upon identification of the key bottlenecks in 
research that should be overcome to stimulate innovation in the drug development process 1. IMI 
brings the different stakeholders (pharmaceutical companies, Small- and Medium-sized Enterprises 
(SMEs), universities, public research laboratories, POs and healthcare regulators) together in PPPs. 
The IMI is situated at a pre-discovery or proof-of-concept (POC) stage and covers early research to 
improve needed and poorly understood science. The IMI Strategic Research Agenda (SRA), targeting 
key challenges such as safety and efficacy prediction, knowledge management and education and 
training, was implemented to enhance the competitiveness of the pharmaceutical sector in Europe for 
the benefit of patients and scientists 2, 3. In 2009, the first IMI consortia conducting projects 
addressing the SRA key challenges were initiated. Since then, IMI has already launched 49 consortia 
via 11 competitive Calls, and project execution of IMI projects will run until end of 2017 4. The total 
budget allocated to IMI is 2 billion euros (2008-2014), money equally invested by the EC (cash 
contribution) and EFPIA (in-kind and cash contribution) 5, 6.  
The progress in view of the planned activities, the main achievements, and information about the 
bibliometric outcomes of IMI’s consortia in terms of publications, citation impact as well as co-
authorship patterns are continuously monitored by the IMI Executive Office (IMI EO) and evaluated by 
external reviewers 7-10. The IMI has been positively evaluated by a panel of independent experts 11-13, 
not at least in view of the creation of IMI 2 under Horizon 2020 in 2014 14. The expert panel prepared 
an executive summary document to support such IMI 2 creation, stating that IMI 2 should build upon 
the lessons learned from IMI 15. IMI 2 has already launched 4 Calls for Proposals.  
The consortia focusing on projects targeting the development of new methods and tools for safer and 
more effective drugs are inherently more prone to Intellectual Property Rights (IPRs) issues than 
consortia focusing on knowledge management projects. The former consortia represent the majority 
of the IMI consortia. With the first IMI consortia heading towards the project end, it is time to take 
stock of the added value and the (so far unexplored) opportunities of the consortia under the 
umbrella of IMI. Currently there is a lack of empirical studies wherein the effectiveness of these 
partnerships is assessed. Not much research has been performed to identify the key components of 
successful PPPs 16-18. We set up a case study analysis to investigate the outputs on the short term and 
the outcomes on the long term of 6 IMI consortia reaching the project end. The specific case studies 
define the (missed) business opportunities and reveal the added value for science and society.  
Box 1: IMI in Numbers 19  
23 patient organizations (POs), 14 regulators, 714 academic & research teams, 410 EFPIA teams, 135 
SMEs, More than 6000 researchers, 61% of projects reported some form of patient involvement, 12 
regulators on boards of projects, 50% of projects have representatives of regulatory authorities on 
scientific advisory boards.  
 
RESULTS 
Launch of the projects and scientific deliverables 
The scientific deliverables of the selected IMI PPP projects are listed in the Description of Work, the 
detailed project plan agreed by the partners before the project start and are in line with the reviewed 
Project Proposal. In 2 projects, some delays to start have been reported, e.g. U-BIOPRED faced 
scientific delay due to the withdrawal of a partner, but has managed to attract new partners and 
made up for the loss of time and funding. Another example was SUMMIT that faced significant 
scientific delays due to an unexpected higher grade of complexity for sample selection for the Genome 
Wide Association Study (GWAS) and accompanying work on phenotype definitions as well as on the 
design and negotiation of data and material transfer agreements, further also a change of scientific 
strategy aspects due to reappraisal of the SUMMIT strategy for genetic discovery based on current 
state-of-the-art. However, the delays have been argued elaborately in the Periodic Reports and have 
been evaluated and commented by an Independent Expert Panel. The delays have all been eliminated 
in the course of the project. In the 6 consortia analyzed, numerous scientific outputs have been 
delivered, including research tools such as rat and mouse models, biomarkers, software tools for 
biomarker identification or toxicity prediction and new and improved imaging techniques (Table 1).  
Table 1. Main scientific results from the 6 IMI projects analyzed 
Imaging techniques 
 Non-invasive method (patent appl) (SUMMIT) 
 Touchscreen cognitive testing platform (NEWMEDS) 
 Probe (erf meld) (SUMMIT) 
Stratification tools and methods (SUMMIT, IMIDIA, NEWMEDS) 
 Individual biomarkers 
 ‘Omics’ platform – Phenotype handprint (U-BIOPRED) 
 Clinical trial design criteria (NEWMEDS) 
Animal models (SUMMIT (rat – patent appl), NEWMEDS, U-BIOPRED) 
Software tools 
 Predictive models (SUMMIT, eTOX) 
 Open, interoperable information platform (Open PHACTS) 
Research tools 
 Human prancreatic β-cell line (IMIDIA) 
Antibodies (SUMMIT) 
 
Clinical trial design criteria have been designed, clinical trials have been set up and biosamples have 
been collected in (centralized) biobanks. Large unique datasets have been combined in massive 
database constructs. The scientific excellence is reflected in the number of highly-cited papers  (Fig.1) 
10.   
 
Fig. 1 – Thomson Reuters’ Figure on Paper Numbers, 4-year average citation impact and share of 
highly-cited research for the selected IMI projects – Call 1 (the figure has been adapted to display 
only the projects analyzed in this case study) – The average citation impact of all research-based 
projects is above world average (1.0) and the percentage of highly-cited research is above world 
average (10%). Research associated with NEWMEDS is cited over twice world average and research 
associated with U-BIOPRED is cited nearly three times world average (2.96). This shows the scientific 
excellence of the research performance of IMI-associated research 10. All rights reserved. Reproduced with 
permission from IMI JU. 
 
Table 2. Summary patent applications for 6 IMI projects analyzed in the case study 
Project Patent title Patent number Priority date Applicant 
IMIDIA Human pancreatic beta 
cell lines for diagnostic 
of diabetes 
EP2121905A1, 
US20110318389 
Feb. 21, 
2007 
Sarl Endocells, Institut 
National de la Santé et 
de la Recherche 
Médicale (INSERM), 
Centre National de la 
Recherche Scientifique 
(CNRS) 
SUMMIT A new ultrasound-based 
method for non-invasive 
assessment of 
atherosclerotic plaque 
Data not yet 
available 
Data not yet 
available 
Data not yet available 
SUMMIT A rat model for diabetic 
complications 
Data not yet 
available 
Data not yet 
available 
Data not yet available 
SUMMIT Desmosine assay as 
biomarker of 
extracellular matrix 
degradation and 
vascular disease 
Data not yet 
available 
Data not yet 
available 
Data not yet available 
Table 2 – Summary patent applications for 6 IMI projects analyzed in this case study. The SUMMIT 
patent applications are the result of the project progress. The IMIDIA patent application was used as 
background IP included in the project by Endocells SARL1. Data is extracted from the 2nd Thomson 
                                               
1
 A new patent filing to protect technologies for the creation of third generation human beta cell lines is being 
prepared in the IMIDIA consortium 
20
 – This information has been provided by IMI JU recently, and was not yet 
available at the time of the IMI Case Study.  
 
Reuters bibliometric analysis report for IMI 9 and updated with patent information found on Espacenet 
21. Note that IMIDIA and SUMMIT are Call 1 projects. 
 
Legal (IP) management  
With respect to the IP management different practices have been revealed across the 6 studied 
consortia. Basic research projects are more prone to patenting research results and keeping trade 
secrets whereas knowledge management projects focusing on database creation and development of 
software models are more subject to sui generis database protection 22.  
In the 6 projects, the management of IP is case-specific, negotiated at the project start in line with 
the IMI IP Policy 23, and contractually defined in the Project Agreement. For example, the background 
IP remains the ownership of the original party, while the project partners have royalty-free access 
rights to the background IP to achieve the project objectives 24. 
Patent management 
The management of patents was particularly debated with the IMIDIA project representatives. In the 
IMIDIA project, a patented cell line has been brought into the consortium by a SME as background IP 
(Table 2). The patented cell line remained the ownership of the SME Endocells SARL.  
In projects prone to patentable results, Project Coordinators can advise consortium partners on 
potential patentable results, but generally, patenting research results is a decision made at the Work 
Package (WP, see further) level, by the party (i.e. large pharma company, biotechnology SME or 
academic partner) responsible for executing the particular research. Partners are subject to 
confidentiality and unless otherwise agreed, results are not made publicly available in scientific 
publications or via patent applications, but are kept as trade secrets among the partners involved. As 
agreed by all consortium partners, and consistent with the IMI IP Policy 23, foreground IP is owned by 
the partner(s) generating it 24.  In every project studied, the research results achieved and subject of 
a (potential) patent application are solely owned. Both the public and private partners carefully 
consider filing patent applications on the scientific achievements.  
Across the 6 cases studied, few patent applications have been filed (Table 2) 7. Moreover, since the 
number of applications specifically generated by IMI projects to date is small, and publication of such 
data lag behind (patent applications are only published 18 months after their initial filing date), the 
IMI has advised not to consider patent analyzes as parameters in the 2nd, 3rd and 4th bibliometric 
analysis of ongoing projects 8-10.  
According to the participants in the case study, the management of patents is strategically and 
thoroughly considered. Not all patentable results are patented by default. Partners state that securing 
access rights to basic technologies is more important than claiming patent protection. In some 
collaborations within the selected IMI projects, participants stated that patents on early stage 
inventions would have hindered smooth collaboration. In IMIDIA and NEWMEDS, for example, new 
research tools, such as animal models, have been developed. Instead of patenting those research 
results, thereby potentially hindering further research and forcing participants having to deal with high 
patent maintenance costs, the choice to keep the research results as trade secret is made and based 
upon this strategic decision; the non-patented animal models will be licensed out to academia and 
pharma. In the IMI project U-BIOPRED, dedicated to the classification of patients suffering from 
severe asthma to enable more personalized and targeted treatment, it was agreed by all partners that 
the research results, especially biomarkers, would be made publicly available, bearing in mind the 
Myriad debacle2. Knowledge about the patentability of results, especially biomarkers, among the 
researchers, however, is limited.  
Data management 
In all 6 projects analyzed, databases have been developed. The databases combine non-confidential 
and confidential datasets from public and private partners leading to datasets which, due to their size, 
allow for new insights and approaches. Every party remains owner of the data provided. The database 
producers, mostly 1 or 2 consortium members, own a sui generis right on the database 22. Access 
rights to the database may vary. In some cases, all project participants can freely access the 
                                               
2
 Myriad aggressively enforced its patents on two human genes associated with breast and ovarian cancer (BRCA1 and 
BRCA2). The US lawsuit alleges that those patents were invalid and unconstitutional (Association for Molecular Pathology v. 
Myriad Genetics, 569 U.S. 12-398 (2013)) 
25
. It was argued by proponents that those patents were stimulating research by 
making the results from genetic research publicly available in a patent, and that these were essential for investments in 
biotechnology. Opponents argued that the claims were not valid as they claim non-inventive genetic information (a product 
of nature). They warned for patent thickets, they stated that these patents were stifling innovation by preventing others 
from conducting cancer research, and patients seeking genetic testing were limited in options. After intense legal 
proceedings, on June 13, 2013, the Supreme Court unanimously invalidated some of Myriad's claims to isolated genes. The 
Court held that merely isolating genes that are found in nature does not make them patentable. 
 
database, whereas in other projects, only certain WP members can access and use the database. 
Regarding the access rights for third parties, no detailed rules are designed yet for the selected 
projects.  
In case of the knowledge management projects eTOX and Open PHACTS, wherein the development of 
a knowledge platform is the key objective, the platform with the databases is owned by the consortia 
as a whole and managed by a partner specialized in the establishment and maintenance of databases. 
A first way of data management, in such type of projects, is the creation of a knowledge platform 
combining public and company data, whereby data can be extracted by users using a Creative 
Commons-based licensing framework (Open PHACTS). Another way is by creating a similar knowledge 
platform, whereby company-specific and highly confidential data, safeguarded by an honest broker 
(see below), are included into the platform and where data can be accessed according to a layered 
security level (eTOX).  
The studied IMI projects focused on basic biomedical research (IMIDIA, SUMMIT, NEWMEDS and U-
BIOPRED) are all considering sustainability plans for the data and databases generated and explore 
ways to guarantee continuous information upload and extraction from the database. The ownership of 
the database is not the participants’ major concern, the accessibility of confidential information it 
contains, on the other hand, is.  
Project management  
Operational organization 
Both a public and a private partner, often assisted by an administrative project officer, coordinate 
each consortium/project. From the project start, this ‘coordination team’ deals with scientific and 
organizational daily business. Each project is divided into WPs, wherein even so both an industrial and 
an academic representative take the lead. According to the interviewees, the scientific tasks are 
allocated according to the parties’ (academia or industry) capabilities to perform the research. A 
myriad of project management tools are used and developed to optimize the operations of such multi-
stakeholder partnerships, such as a traffic lights system to monitor the progress of WP tasks and the 
Quarterly Monitoring Reports (QMRs) providing an accurate and summarized overview of the projects’ 
progress. 
Honest broker model 
It was a true challenge for the pharmaceutical companies to share non-confidential, and more 
importantly, and new to the sector, confidential data with consortium partners, which are considered 
future competitors. The honest broker model, whereby one neutral trusted party supplies a data 
warehouse (i.e. a computer system for staging, integration and access of data) (Fig. 2), is a model 
that convinced the companies to increase their level of openness with respect to (confidential) data 
sharing. For example, to build the toxicology information database in the eTOX consortium (eTOXsys), 
the companies share two types of data with an honest broker: non-confidential data, available to 
other consortium partners, and confidential data. The confidential data is only accessible by the owner 
thereof. The different sets of confidential data are anonymized when integrated and can only be 
access by the honest broker. The more companies share non-confidential but also confidential data, 
the more data is available to train toxicity prediction models that serve all parties.  
 
Fig. 2 – The honest broker model used in eTOX. Reproduced with permission from Synapse Research Management 
Partners. 
 
Another example is the open access innovation platform in the Open PHACTS project, called Open 
Pharmacological Space (OPS). The platform comprises data, ontologies (i.e. vocabularies) and 
infrastructure needed to accelerate drug-oriented research by intelligent interrogation of the system. 
Due to the amount of information, and the possibility to correlate the information coming from 
different sources, researchers are triggered to define new and innovative research questions and think 
outside the box, or even think in new boxes, for research design. The large Open Source and Open 
Data services allow secure querying for data, the ‘plug-in’ of proprietary data sources and analysis 
services and the demonstration of the value of semantic web technologies by establishing a user-
friendly semantic data integration infrastructure. The sustainability of the system after the project 
(end 2014) is guaranteed by the Open PHACTS Foundation, a non-profit organization which functions 
as honest broker and runs the Open PHACTS Discovery Platform. The Open PHACTS Foundation 
participates in BigDataEurope’s Horizon 2020 (H2020) project, which aims to integrate different big 
data infrastructures into a stack of interoperable data assets 26. The Foundation will further act as 
contact point with the life science R&D community, organizes workshops and runs pilot project with 
other sectors 26. Dependent on the amount of information shared by the user, different membership 
levels for partners, associated members and third parties are defined.  
Standardization efforts  
The studied IMI consortia have invested in standardizing and harmonizing protocols and agreements 
to facilitate communication, increase trust and improve efficiency and reproducibility, transferability 
and validation potential among partners. For example, Material and Data Flow Principles have been 
developed by IMIDIA and SUMMIT to deal with the sharing of IP within the consortium and between 
different consortia (Fig. 3). Those consortia agreed upon a Memorandum of Understanding (MoU) to 
improve knowledge transfer and reduce duplication. The MoU was later also signed by DIRECT, 
another diabetes-specific research project in the IMI. The MoU forms the basis for The IMI Diabetes 
Platform, a collaborative effort of 3 IMI consortia (IMIDIA, SUMMIT and DIRECT) to jointly overcome 
key bottlenecks on the way to innovative diabetes therapies. This data sharing model allows the 
project participants of the IMIDIA, SUMMIT and DIRECT consortia to exchange information between 
the projects. The consortia created an information platform wherein project results, by the consortium 
members identified as being potentially interesting for other diabetes-projects, are shared. The MoU 
defines the flow of information, e.g. when research results (foreground IP) from the IMIDIA 
consortium are interesting to be explored in view of the SUMMIT scientific activities, both consortia 
sign a subject-matter specific Confidentiality Disclosure Agreement (CDA). If the exchanged 
information requires exchange of materials (e.g. a specific cell line), the consortia will additionally sign 
a Material Transfer Agreement (MTA), together with a General Transfer Agreement formally 
identifying the information and material exchanged as foreground IP owned by (a) member(s) of 
IMIDIA. This foreground IP can then be transferred and used as background IP in SUMMIT. In case 
the use of such information (and/or material) exchange generates new findings within SUMMIT (i.e. 
SUMMIT foreground IP), the General Transfer Agreement states that this SUMMIT foreground IP 
automatically needs to be transferred to IMIDIA as SUMMIT background IP (Fig. 3).  
Fig. 3 – Memorandum of Understanding (MoU) between the IMI Diabetes projects. Reproduced with 
permission from IMI JU. 
 
Other standardization efforts are for example present in SUMMIT and U-BIOPRED, which have put 
particular efforts in unraveling the complex regulatory patchwork of national legislations. The 
consortia dealt with the challenges in the handling of human samples and related data in multi-
national setting and in accordance with all relevant legal provisions and project agreements. The 
existence of a web of complex and diverse country specific regulations and specifications across 
Europe was a major hurdle for research. Another example is the standardization efforts of the 
NEWMEDS and the U-BIOPRED consortia wherein new clinical trial criteria have been developed, 
shortening time, reducing costs and thus improving the time to bring medicines to the patients. For 
example, in NEWMEDS the real opportunity resulting from this key achievement is the proposed 
reduction in duration of clinical trials in patients suffering from schizophrenia from 6 to 4 weeks and a 
number of patients needed, from 79 to 46. The estimated cost reduction is €2.8 million. According to 
the IMI representatives interviewed, the early involvement of the European Medicines Agency (EMA) 
is pivotal at this level. 
Involvement of Small and Medium-sized Enterprises (SMEs) 
The IMI Case Study revealed that in all the consortia analyzed, one or more SMEs participate. IMI 
consortia provide a platform for SMEs to have their technology validated or tested by pharmaceutical 
companies. For example, in IMIDIA, the SME Endocells SARL has its human pancreatic beta-cell line 
validated within the project by the pharmaceutical companies (Table 2). In the project eTOX, 4 
biocheminformatic SMEs participate to develop prediction models. As pharmaceutical companies are 
the target customer of biocheminformatic SMEs, participating SMEs have the advantage of having 
their software models, brought in as background IP or generated within the project, validated by their 
target customer. The validation results are shared with the SMEs, offering them insight in flaws or 
potential improvements to their product. In every consortium, (part of) the administration and 
organizational management is outsourced to an SME acting as project management office(r). In 1 
consortium (SUMMIT), the only SME involved conducts this administrative/management type of 
activity. 
 
DISCUSSION 
PPPs as accelerator of science 
The key objective of IMI 27, 28 is to speed up the development of better and safer medicines for 
patients 17. The multi-stakeholder collaboration model aims at faster, cheaper and better drug 
development 29. Europe had never seen biomedical consortia of this size, with the accompanying 
project management skills required. Although the organizational aspects of participation in consortia 
of such size are not to be underestimated, the PPP approach to addressing the world’s emerging 
health challenges might be one of the key innovations to move science forward.  
There has been some criticism 30, 31 with respect to IMI and there were a myriad of challenges at the 
start of IMI. IMI acted as an umbrella PPP embodying 15 consortia to be launched in the 1st Call. A 
major challenge was that initially IMI could not provide the resources to help the different consortia 
start up the project and support them during the project negotiations. However, IMI has overcome 
this challenge by setting up the IMI EO which currently functions at full speed.   
The participants agree that the scientific results would have never been achieved so rapidly if these 
projects would have been executed in silos or via bi- or trilateral agreements. The scientific 
deliverables are numerous and projects progress considerably, as highlighted during the Interim 
Reviews. What makes the case study analysis unique is the revelation of many more valuable, often 
non-purely-scientific deliverables, of which only little external audit information is publicly available. In 
its review report, the expert panel stated that not only the scientific excellence needs to be 
demonstrated, but that it is essential to prove the impact and added value for the society beyond 
scientific excellence 15. Building databases and information exchange platforms of the size and scale 
experienced in IMI’s consortia is innovative. By sharing (non-)confidential information, competitors 
become colleagues striving towards a common goal. 
Business plan and datasets’ sustainability  
Time has come to invest in setting up business plans for exploitation of the outputs. The 6 consortia 
are reviewing their sustainability plan. Strategies such as licensing out patented and trade secret 
protected inventions or involving multinational industries to produce prototypes of research tools 
developed, obliges the participants to consider carefully the market value of the research tools 
developed. The IMI EO could offer support to the consortia to set up such business plan and/or 
transition plan.  
The sustainability of the datasets produced requires serious reflection. The amount of collected, 
combined and shared data has never been experienced in pharma. In all IMI consortia analyzed, 
databases are created allowing researchers to explore combined datasets with different access and 
security levels. Databases combining publicly available information with (non-)confidential data of 
different partners offer researchers insight in an integrated set of data which exceeds the size of any 
existing dataset. The size of the IMI projects implies a new way of doing research. Researchers are 
challenged to interrogate databases in a more complex way. It would be a tremendous loss if the 
databases created would not be maintained or if the information flow would be stopped after the end 
of the projects. To explore the different options for datasets’ sustainability, guaranteed information 
upload and extraction from the database, the data sustainability model developed by Open PHACTS, 
could serve as a role model for other IMI consortia. The EC has stressed the need to explore options 
to support the datasets’ sustainability 32.  
IMI’s Best Practices Forum 
The knowledge gathered in the different IMI projects exceeds pure scientific results. Many other 
achievements need to be treasured. An enormous amount of templates, harmonized protocols and 
standardization endeavors for information exchange have been developed within and between 
consortia. It took the consortium members considerable effort and time to harmonize and valorize 
these assets.  
A forum could be created to exchange best practices and disseminate existing knowledge on the legal 
and regulatory landscape. ‘IMI Consortium Guidelines and Best Practices’ could be set up; a list of tips 
and tricks including topics such as governance, IP, dissemination of results, could be distributed 
among the (especially new) consortia to facilitate the start-up of new projects. 
Intra- and inter-consortia collaborations 
Collaborations between different IMI consortia have been established (e.g. between IMIDIA, SUMMIT 
and DIRECT, but also between the IMI projects eTOX and Open PHACTS, DDMORE, EMIF, EU2P, MIP-
DILI, PREDECT and EHR4CR). These collaborations are strongly encouraged by IMI EO. Further, there 
is also a MoU signed between the umbrella PPP IMI and its US counterpart Critical Path Institute (C-
Path) 33 alongside with the Juvenile Diabetes Research Foundation (JDRF) and the Clinical Data 
Interchange Standards Consortium (CDISC). Such international collaborations are necessary to avoid a 
potential overlap between the different collaborative initiatives worldwide.  
IMI’s IP Policy  
The collaborative PPP model of IMI, engaging the pharma industry as well as (academic) research 
institutes, challenges the business model of industry as well as the ‘protective behavior’ within 
academia 34, 35. For many years, IP figured as a key asset for industry as well as for (academic) 
research institutions 35. Taking industry more than 10 years back, nearly every patentable invention 
was protected with a patent at very early stages. Academia, being aware of that approach, adopted a 
similar ‘pro patent’ attitude 36. However, history learned that, down the road towards exploitation, 
many such patented inventions turn out not being useful for further development, as in reality for 
instance, only a few lead compounds or therapies survive the challenging Phase 3 trials and make it to 
the market 37. The business model of industry (and academia) consisting of patenting inventions very 
early onwards becomes too costly, too risky and unsustainable 37.  
Hence, industry diversified its business model. The idea is that, in order to speed up drug 
development, early inventions need to be shared smoothly, and preferably in an atmosphere of open 
collaboration 38, 39. Patents remain important as protective instruments from the moment that market 
opportunities crystallize out or are envisioned in the future. Some academic institutes have a similar 
understanding. However, since spin-out initiatives are important business activities of academia, early 
inventions are still screened thoroughly at academic institutes for patentability 40. 
The criticism that the influence of business entities in IMI projects is too big should be reconsidered 30, 
41. EFPIA’s influence is not to be underestimated: the pharmaceutical industry decides on the Call 
topics, which are in line with the needs defined in the SRA 2, 3. This should not come as a surprise, 
since the association of main pharmaceutical companies counts for half of IMI’s budget. Moreover, 
EFPIA companies will do exploitation of a large part of the results; hence, it is understandable that the 
research topics and the expected deliverables are in their interest and in line with their business 
strategy. Although EFPIA’s ownership and responsibility of the SRA should not be diluted, the scope 
and priorities should be defined by a broad group of stakeholders in a clear and transparent way 15. 
According to the results of this study, the idea that EFPIA partners claim all the research results 
(foreground IP) is not correct. All interviewees experienced the IMI IP Policy 23 as a good and flexible 
framework to start negotiating the ownership and access rights on background IP and foreground IP.  
Some IMI projects under study (SUMMIT, IMIDIA) delivered patentable inventions (Table 2). Clear 
and well-reasoned approaches are taken towards patenting and not all inventions are patented right-
away. This trend could be explained by the tendency to validate research results thoroughly and to 
screen the interest of industry. Further, access rights to basic technologies are preferred above 
ownership as such. With respect to jointly developed inventions, co-ownership is possible within IMI 
projects, but avoided; commercially this may lead to more complex situations around more validated 
outcomes. The flexibility of the IMI IP Policy 23 is the basis for negotiations between the partners on 
ownership in the interest of the potential commercialization of the developed foreground IP 24.  
The IP framework provided by IMI is considered by the interviewees adequate for the selected IMI 
projects. The template Project Agreement was experienced as transparent and tailor-made 
adaptations to the needs of the consortium are possible. IMI has already done some reasonable 
efforts to explain the IP Policy 23 which was made publicly available in 2007. In 2008, the IPR 
Helpdesk issued an Explanatory note 42, in 2009 the IMI EO published a Clarification note 43 and in 
2010, there was an additional IP Guidance note 44. A recommendation resulting from this Case Study 
was to harmonize this set of documents into a revised IP Policy, explaining the concepts, the rules and 
the differences with the FP7 rules and the Horizon 2020 rules, illustrated with relevant and case-based 
examples3. This has been done at the launch of IMI 2. Also, available policy documents contain limited 
information with respect to data management and sample sharing, which needs to be further 
elaborated.  
SME participation in IMI projects 
At the start of IMI, it faced criticism regarding its IP framework. Some organizations representing 
SMEs, e.g. Flandersbio, or academia, e.g. the League of European Research Universities (LERU), 
argued strongly against participating in precompetitive PPPs, especially in the context of the 
controversial IP framework presented by the IMI 30, 31. In a subsequent LERU letter (2013) it was 
stated that ‘the IP terms seem to concentrate on the marketing of pharmaceutical and diagnostic 
                                               
3
 This recommendation was included in the IMI Case Study Report presented to the European Commission, 
EFPIA, and the IMI JU. The recently issued IMI 2 JU Model Grant Agreement has implemented the IMI IP Policy 
into its Model Grant Agreement (Section 3 - Rights and obligations related to background and results, Art. 23a 
to Art. 31) and has implemented the information presented in the Explanatory Note, the Clarification Note and 
the IP Guidance Note therein 
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developments by EFPIA partners, rather than giving equal weight to the interests of academic or SME 
partners, which might be to undertake further research or to put the results in the public domain’ 46.  
In a joint publication, four SMEs participating in eTOX have expressed their disagreement with the 
criticism on the proclaimed low number of biotechnology SMEs participating in IMI projects 30, 31, 47, 48. 
They underline the importance of their participation in and contribution to the project 48. The initial 
fear to jeopardize the SMEs’ business model through participation in IMI projects (by making their 
background IP freely available to a large part of the customers) has disappeared and should no longer 
impede SMEs applying to participate in IMI projects.  
At first sight, the incentives for biotechnology SMEs to participate in IMI projects are not obvious. 
Suppliers and customers sit at the same table, access rights on background IP and foreground IP are 
freely available during the project, while after the project, the access rights for project participants to 
IP are to be negotiated (conditions vary from ‘for free’ to ‘on fair and reasonable conditions’). 
Although the larger part of SMEs’ target customers (i.e. the large pharmaceutical companies) are 
present in IMI consortia, and hence, no or no major profits can be made by exploiting foreground IP 
developments during the project itself, these projects offer SMEs the opportunity to create technical 
standards and to occupy a preferred position in the market. The advantages of participation outweigh 
the disadvantages; being partner in the consortium acts as a business multiplier, participating SMEs 
have closer contacts with participating pharmaceutical companies, new (business and scientific) 
models and (research) tools are validated by the target customer, etc. For example, SMEs 
participating in eTOX will receive a maintenance fee from the other eTOX participants when they use 
the predictive models developed by SMEs within the project. This maintenance fee is expected to be 
lower than a normal license fee that the SME would receive to provide access to the predictive model 
to non-participants. However, these maintenance fees are assured, and through the SME’s 
participation in such consortia, they develop new business opportunities. Further, by participating in 
consortia, SMEs gain access to large amounts of (before not accessible) anonymized data which 
enables them to improve models outside the field of toxicology. Another example is IMIDIA, where 
the SME ‘Endocells SARL’ has the opportunity to validate its human beta cell line as an innovative 
research tool by its target customers, and potentially creating a new standard for safety and efficacy 
testing of diabetes drug compounds. 
There is a major role cut out for biotechnology SMEs participating in IMI consortia. Pharmaceutical 
companies lack bio-informaticians familiar with ‘wet’ experiments 49 and lack the resources to develop 
important research tools. Development of those tools, diagnostic equipment, database models and 
applications are core technologies of many biotechnology SMEs. These tools and (software) 
applications can be built, tested and validated within such multi-stakeholder constructs, which is of 
extreme value for SMEs. For instance, under the organizational framework designed in the selected 
IMI projects, the pharmaceutical companies share the validation results with the SMEs, which is not 
always the case in bilateral agreements.  
There are also biotechnology SMEs which aim at bringing medicinal products to the market. Such 
SMEs face a difficult position within IMI projects, as they may be competitors of the EFPIA member 
companies participating in the respective projects. One might argue that competition drives innovation 
and stimulates the project progress. Such biotechnology SMEs might see participation in large IMI 
consortia as an opportunity to compete, to acquire or gain brand awareness or to be acquired by a 
large pharmaceutical company, e.g. deCODE Genetics, Inc. (Icelandic: Islensk erfdagreining, based in 
Reykjavik) that joined the NEWMEDS consortium as a biotechnology SME. In December 2012, 
deCODE Genetics was acquired by Amgen. Nevertheless, biotechnology SMEs should be fully aware of 
their position within the consortium, their strengths and weaknesses, the disadvantages and the 
benefits of participation before joining the consortium, so they can adjust their strategy accordingly. 
However, due to the IP position/dependence and often limited resources within SMEs, there is still 
room for IMI 2 to improve the framework for biotechnology SMEs to participate in research activities. 
It remains to be seen whether a PPP in general is the ideal construct for SMEs to share and develop 
their core technology. 
 
CONCLUSION 
In conclusion, the case study on the business and IP opportunities and on the potential value gap 
within IMI projects supports the insight that there has been achieved a myriad of opportunities within 
the IMI consortia. IMI delivers beyond scientific project results by putting in place tools and 
mechanisms aimed at translating the scientific results in exploitation opportunities 19. The study 
thereby largely supports the recommendations of the expert panel’s review report to prepare the IMI2 
creation 15. Six IMI projects from the 1st and 2nd Call were studied and experiences of participants 
were examined, dating back from a time where the activities at IMI EO were at its infancy (2008-
2009). Meanwhile, the IMI EO has set up many new consortia, gained expertise in the complex 
domains of organizing and governing large-scale multi-partner public-private consortia and provided 
clear and professional guidance to IMI projects. Further actions, both on the consortium level, as well 
as at IMI level, are needed to guarantee the sustainability of IMI project results. Several initiatives 
may improve future activities. A forum to exchange best practices and disseminate existing knowledge 
on the legal and regulatory landscape within Europe would help future PPPs to save time and energy. 
A data support system could be set-up to sustain the different databases constructed during the 
project. Several IMI project databases could be linked to each other and potentially to other PPP 
databases on a European or worldwide scale (e.g. the European Strategy Forum on Research 
Infrastructures (ESFRI) or Biobanking and Biomolecular resources Research Infrastructure (BBMRI-
ERIC) platforms). The honest broker model is considered to offer trust to pharmaceutical companies 
to share their non-confidential and moreover, their confidential data on specific conditions. The honest 
broker could serve as a data warehouse and facilitate the valorization of these assets. More case-
based evidence is needed to explore how the sustainability of the projects will progress beyond the 
project life span, and especially, what will be done to capture the value of the knowledge created.  
The continuation of IMI is secured as IMI 2 has been launched in 2014. IMI 2 will further promote 
investment in Europe and encourage collaboration with other healthcare groups, such as imaging and 
diagnostics 19. The budget has been raised to 3.3 billion euros, and the life cycle of IMI 2 will be 10 
years. Being the world’s largest PPP operating in the precompetitive and even POC phase in the 
health-care sector, IMI serves as a role model for many other collaborative models worldwide 17. 
Collaboration of large pharmaceutical companies, SMEs, academic institutions and public bodies speed 
up drug development 50. Optimization of IMI as a successful PPP could serve healthcare and patients 
in general 6.  
 
METHODS 
Case selection 
The qualitative empirical case studies were performed on behalf of the IMI EO under a service 
contract procedure. Six IMI consortia were selected in a joint meeting of KU Leuven and the IMI EO 
and based on the focus areas defined in IMI’s SRA (predicting safety, predicting efficacy, knowledge 
management and education and training) 2, 3, 51, the variety of expected deliverables, different 
approaches towards protection of Intellectual Property (IP) and the expected project end. The 
selected consortia target problems in different fields, ranging from neuroscience (NEWMEDS), 
metabolic disorders (SUMMIT, IMIDIA) and respiratory diseases (U-BIOPRED) up to knowledge 
management projects such as development of platforms for toxicity prediction (eTOX) and integrated 
pharmacologic data (Open PHACTS). Five consortia were Call 1 projects (SUMMIT, IMIDIA, 
NEWMEDS, eTOX and U-BIOPRED) with project duration of 5 years. The sixth consortium was a Call 2 
consortium with expected project duration of 3 years (Open PHACTS)4; this project was selected to 
review how sustainability of the achievements is organized.  
Document analysis 
Per IMI consortium, the case study involved an in-depth analysis of public as well as confidential 
documents signed under a NDA (Descriptions of Work, Project Agreements and Amendments thereof, 
Periodic Reports, Interim Review Reports). The documents were used to reveal the project progress in 
terms of the pre-set milestones to reach the different project objectives. Specific attention was given 
to the way IP was handled within the consortium, as well as the long-term view on the sustainability 
of the project outputs, i.e. the short-term project deliverables, and the outcomes, i.e. the difference 
these deliverables could mean for science and patients in the long term. The project documents have 
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 Due to the success of Open PHACTS, this project has been prolonged until February 2016 via a 1
st
 Call for 
Proposals to ‘Explore New Scientific Opportunities’ (ENSO) granting awarded on-going IMI projects the 
opportunity to explore new scientific opportunities through awarding them an additional research budget. Also 
eTOX, SUMMIT and IMIDIA and U-BIOPRED have been awarded such ENSO grants.  
further been analyzed in view of the econometric analyzes performed by Thomson Reuters and the 
EC’s Independent Expert Panels’ evaluation reports 7-12, 15-18. 
Semi-structured interviews 
From March 22 to Sept 25, 2013, interviews with consortium representatives (project coordinator, 
managing entity, legal experts and/or the project officer) were performed via telephone conferences 
and face-to-face meetings. Interview questions related to the project specific scientific output and 
valuation, IP, collaboration, SME involvement and sustainability of results generated. The interview 
results have been analyzed based on the thematic framework approach 52, 53. From these results, 
several opinions are formulated and expressed through recommendations for the Consortia as well as 
IMI to optimize the functioning of the IMI. The recommendations have been presented at the IMI 
Governing Board in October 2013, chaired by dr. Rudolf Strohmeier, Deputy-Director General of DG 
RTD at the EC. 
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